Watchlist Price Alert

Emergent BioSolutions Inc... (EBS)

NYSE: EBS · Real-Time Price · USD

5.13

0.21 (4.27%)

At close: May 02, 2025, 3:59 PM

5.24

2.04%

After-hours: May 02, 2025, 07:57 PM EDT

4.27% (1D)

Bid	5.06
Market Cap	279.02M
Revenue (ttm)	1.04B
Net Income (ttm)	-190.6M
EPS (ttm)	-3.6
PE Ratio (ttm)	-1.43
Forward PE	5.92
Analyst	Buy

Ask	5.44
Volume	719,507
Avg. Volume (20D)	1,232,587
Open	5.04
Previous Close	4.92
Day's Range	4.94 - 5.29
52-Week Range	3.36 - 15.10
Beta	2.15

About EBS

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers B...

Sector Healthcare

IPO Date Nov 15, 2006

Employees 900

Stock Exchange NYSE

Ticker Symbol EBS

Website https://www.emergentbiosolutions.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 192.11% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-8.69%

Emergent BioSolutions shares are trading lower aft... Unlock content with Pro Subscription

5 months ago

+19.57%

Emergent BioSolutions shares are trading higher after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention

News

2 months ago · seekingalpha.com

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Offi...

2 months ago · zacks.com

Emergent Biosolutions (EBS) Q4 Earnings Top Estimates

Emergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago.